Ocular Surgery News Today

ZUG, Switzerland, May 30, 2024 -- Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members...

Following the achievement of two positive key late-stage clinical milestones on its lead product candidate OCS-01 and recent listing on NASDAQ, Oculis is strengthening its executive leadership team with the appointment of Rebecca Weil, Ph.D., seasoned global ophthalmology commercial executive, as Chief Commercial OfficerOCS-01’s recent positive topline results in Phase 3 DIAMOND Stage 1 trial for diabetic macular edema (DME) and in Phase 3 OPTIMIZE trial for inflammation and pain followin...

Ocular Surgery News | We read, with great concern, the recent article regarding workforce challenges in pediatric ophthalmology (Healio/Ocular Surgery News, Jan. 25, 2023, page 1).The article focuses on reimbursement decreases, decline in pediatric ophthalmology fellowship match rates, and access to care for specialized pediatric eye care and strabismus management, but the headline labeling this an “economic

Press Release: Oculis Strengthens its Scientific Advisory Board with World-Leading Ophthalmology Experts to Support Pipeline Development Oculis Strengthens its Scientific Advisory Board with World-Leading

Virtual Webinar to Take Place Friday, October 14th @ 11 AM ET Topline Results from ZETA-1 Phase 2b Trial of APX3330 Expected Later in 4Q 2022 FARMINGTON...

Garden City, New York (PRWEB) August 24, 2022 -- New York, NY – August 2022 – OCLI Vision is proud to announce that five OCLI Vision doctors have been named

Peter K. Kaiser, M.D., a world-renowned ophthalmologist and retinal disease expert, to serve as Chief Medical Advisor – RetinaRabia Gurses Ozden, M.D. promoted to Chief Medical OfficerMichael Goldstein, M.D. to transition from Chief Medical Officer and President Ophthalmology to Chief Strategy AdvisorBEDFORD, Mass.-...

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

Highlights of Recent Positive Data from Nyxol's Phase 3 Registration Trial Roundtable Discussion by 3 KOLs with Unique Perspectives and Distinct Patient ...

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...